🇺🇸

US SEC Filing Intelligence

· daily

US SEC Filings Daily Market Digest — September 25, 2026

Today's filings reveal a market bifurcated between high-stakes corporate actions (mergers, asset sales, activist stakes) and routine governance updates. Key themes include significant M&A and restructuring activity (VerifyMe/OpenWorld merger, Titan International's $285M divestiture, Quality Industrial's complex share exchange), activist investor positioning (Jewett Cameron 13D filing), and leadership transitions at major firms (Monster Beverage, Circle, Nextdoor). Period-over-period data is sparse, but forward-looking statements highlight major catalysts: Elroy Air's $175M PIPE and Army contract, Tamboran's first gas sales, and Pulmatrix's reverse merger. Insider activity is mostly routine grants, but a notable director sale at Cypherpunk Technologies ($662K) and a large insider award at Janus International ($750K retention RSUs) stand out. The overall sentiment is cautiously optimistic, with several 'mixed' filings reflecting the uncertainty inherent in pending deals and restructurings.

42 high priority 8 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — September 25, 2026

The two filings for the S&P 500 Healthcare stream reveal a quiet period with no financial results or forward guidance, but significant corporate actions and insider activity. The dominant theme is Medtronic's high-materiality separation of its MiniMed diabetes business, a major strategic pivot that will reshape the company's portfolio and unlock shareholder value. In contrast, Abbott Laboratories shows a routine, non-discretionary insider transaction from a director, which carries low signaling value but confirms compliance with standard equity compensation practices. The absence of period-over-period financial data or guidance in either filing limits trend analysis, but the Medtronic spin-off presents a clear catalyst for portfolio rebalancing and relative value trades within the healthcare sector. Overall, the digest points to a focus on corporate restructuring and passive insider activity, with no immediate sector-wide themes emerging from the limited data set.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — September 25, 2026

This batch of 21 filings reveals a bifurcated market: a cluster of pre-revenue development-stage companies (Niocorp, Tamboran, SunHydrogen, Propanc, Incannex) are burning cash aggressively while successfully raising capital, creating a high-risk/high-reward dynamic. Conversely, mature operators like Donaldson and Home Federal Bancorp show steady, profitable growth. A notable theme is the prevalence of 'mixed' sentiment (15 of 21 filings), indicating widespread uncertainty. Key period-over-period trends include significant margin compression in manufacturing (Integrated BioPharma) and retail (Cracker Barrel), while energy-related trusts (Marine Petroleum, Amplify) face volume and asset value declines. The most critical development is the severe cash burn and negative equity at CID Holdco, which presents an imminent risk of failure. Portfolio-level patterns suggest a capital-intensive shift towards critical minerals and energy transition, with companies successfully raising large equity rounds despite widening losses.

21 high priority 21 total filings
· daily

US Executive Compensation Proxy SEC Filings — September 25, 2026

The 13 proxy filings reveal a period of significant corporate transformation, with a pronounced shift toward non-traditional value-creation strategies. A clear theme is the use of corporate actions—including reverse mergers, Bitcoin treasury strategies, and redomestication—to unlock shareholder value or address liquidity challenges, often with mixed governance implications. The filings show a bifurcation between stable, well-governed entities like Oracle and Greene County Bancorp, and high-risk, transformative plays at Pulmatrix, Super League, and Lifeward. Period-over-period comparisons are limited in the proxy data, but insider activity and capital allocation decisions provide actionable signals. The most critical developments include the proposed Metaplanet Bitcoin investment at Super League, the reverse merger at Pulmatrix, and the take-private of Weave Communications, each carrying distinct risk/reward profiles for investors.

13 high priority 13 total filings
· daily

US IPO Pipeline SEC S-1 Filings — September 25, 2026

The IPO pipeline for September 25, 2026, reveals a bifurcated market: one traditional operating company (Interpace Biosciences) seeking to raise capital amid severe operational distress, one blank-check company (TCGX Acquisition Corp. II) launching a standard SPAC IPO, and one business combination filing (Snowdrift Parent Corp / Chemomab Therapeutics) reflecting the ongoing de-SPAC trend. Period-over-period trends are limited as these are initial registration statements, but the filings collectively signal a cautious but active market for equity capital formation. Interpace's S-1 highlights a company in crisis—post-Nasdaq delisting, reliant on a single customer, and with no near-term product pipeline—while TCGX's SPAC IPO represents a pure-play bet on management's ability to find a target within 24 months. The Chemomab/Snowdrift combination underscores persistent capital needs in the biotech sector, with Chemomab showing continued operating losses and reliance on multiple financing rounds. The most critical development is Interpace's attempt to go public despite severe headwinds, which may test investor appetite for high-risk, micro-cap diagnostics. Portfolio-level patterns include a lack of insider buying in any filing, signaling management caution, and a reliance on external capital (SPACs, follow-ons) rather than organic growth.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — September 25, 2026

This intelligence stream reveals a concentrated wave of trading suspensions and delisting threats across US exchanges, primarily Nasdaq and NYSE, with 9 of 10 filings representing newly published distress signals. The dominant theme is the failure to maintain minimum market capitalization and bid price requirements, with 5 companies (Silexion, Dyadic, SANUWAVE, Fusemachines, SilverBox Corp IV) facing delisting for breaching these thresholds. A secondary cluster involves financial reporting non-compliance (Netcapital) and sustained net losses eroding stockholders' equity (Southland Holdings, Calidi Biotherapeutics). Notably, two companies—Paramount Skydance Corp and Lumen Technologies—are voluntarily transferring listings to NYSE and Nasdaq, respectively, signaling strategic repositioning rather than distress. The aggregate picture shows a tightening regulatory environment where small-cap and micro-cap companies are particularly vulnerable, with compliance deadlines clustering between October 2026 and March 2028. Insider trading data and forward-looking statements are sparse across these filings, but the absence of insider buying in the face of existential delisting risk is itself a bearish signal. The most critical development is SilverBox Corp IV's immediate trading suspension and forced migration to OTC, representing a total loss of exchange liquidity for its shareholders.

10 high priority 10 total filings
· daily

US Executive Officer Management Changes SEC — September 25, 2026

This digest of 36 filings reveals a period of significant leadership transition across US equities, with CEO changes at AllianceBernstein and CoreCivic, CFO departures at Circle and Stark Focus Group, and multiple C-suite and board appointments. The most material event is the planned retirement of AllianceBernstein's CEO Seth Bernstein, a high-impact succession with a $13.5M compensation package for the incoming CEO, signaling an orderly but costly transition. CoreCivic's CEO resignation due to health reasons is a high-materiality event, though the internal promotion of a seasoned executive mitigates immediate risk. A notable cluster of COO departures is observed across three BlackRock-affiliated funds (Private Credit, Direct Lending, TCP Capital) and BitGo, all citing pursuit of other opportunities, suggesting a potential sector-wide talent reshuffling in asset management and crypto. Worthington Enterprises stands out with strong operational performance (13% YoY sales growth) and a bullish data center cooling catalyst, while Janus International's restructuring signals operational strain despite projected cost savings. Overall, the period is characterized by orderly successions and board refreshments, with no widespread negative trends, but the concentration of departures in asset management warrants monitoring for further instability.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — September 25, 2026

This digest of 36 SEC filings reveals a period of significant leadership transition across US equities, with 10 officer changes (CEO, CFO, COO) and 12 board appointments/resignations concentrated in the week of September 25, 2026. Key themes include orderly CEO successions at AllianceBernstein and CoreCivic, a wave of COO departures across BlackRock's credit funds and BitGo, and a notable cluster of board appointments adding deep operational and technology expertise (e.g., FactSet, Duke Energy, Cencora). While most changes are routine, the departures of Monster Beverage's Americas CEO to Coca-Cola and Nextdoor's President of Products signal strategic shifts. Financially, Worthington Enterprises reported strong 13% YoY sales growth and accelerating data center demand, while Janus International's restructuring ($10.8M savings) and Mosaic's new EVP hire indicate operational focus. The overall sentiment is neutral-to-positive, with no major bearish signals from insider activity or guidance cuts, but the high volume of C-suite changes warrants monitoring for execution risk.

36 high priority 36 total filings
· daily

USA Insider Trading Pulse — September 25, 2026

The September 25, 2026 insider trading pulse reveals a predominantly cautious sentiment among corporate insiders, with 10 notable sell transactions totaling over $14 million, including a massive $10.5M sale by a major Redwire Corp shareholder and a $1.5M sale by Credo Technology Group's CTO. However, insider buying is virtually absent, with only one small $6.6K purchase by a Phio Pharmaceuticals director, signaling a lack of conviction in near-term upside. The data shows a strong pattern of pre-planned 10b5-1 sales at high valuations, particularly in the technology and biotech sectors, while energy and industrial companies exhibit routine tax-withholding dispositions. A notable capital allocation trend emerges at Magnolia Oil & Gas, where executives received substantial equity awards alongside tax withholdings, suggesting a focus on long-term incentive alignment. The absence of forward-looking guidance changes or scheduled events in the filings limits catalyst visibility, but the high volume of insider selling at elevated prices (e.g., Twist Bioscience at $175, Semtech at $172) warrants close monitoring for potential sector rotation.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — September 25, 2026

The US SPAC M&A landscape is showing clear signs of stress and execution risk, with 3 out of 4 filings revealing material delays, regulatory non-compliance, or repeated amendments. NMP Acquisition Corp. and Blue Acquisition Corp. both disclosed extensions to their business combination deadlines, indicating that target companies are struggling to deliver audited financials, a critical de-SPAC hurdle. Future Money Acquisition Corp. received a Nasdaq deficiency notice for late filing, adding delisting risk to its timeline. In contrast, Pinnacle Acquisition Corp. is in a clean, early-stage position post-IPO, actively searching for targets in specialty finance. The aggregate picture suggests a bifurcated market: well-capitalized, newly-listed SPACs are proceeding normally, while older, pre-merger SPACs face mounting operational and regulatory pressures. No period-over-period financial trends (revenue, margins) are available as these are procedural filings without operational data.

4 high priority 4 total filings
· monthly

US Pre-Market SEC Filings Roundup — September 25, 2026

The overnight filing batch (Sep 24-25, 2026) reveals a market dominated by capital markets activity, with several SPAC business combinations and de-SPAC transactions progressing, alongside notable insider selling and a few strategic insider purchases. Key themes include significant insider selling in small/mid-cap names (Aspen Aerogels, Mineralys Therapeutics, Omeros) and a major block trade exit by Wood River Capital from Aspen Aerogels, signaling potential sector rotation or liquidity needs. On the positive side, several companies are executing strategic pivots into high-growth sectors like space infrastructure (Non Invasive Monitoring Systems/Gravitics) and autonomous drones (Elroy Air), while others are strengthening governance (BOXABL, Clover Health). Capital allocation trends show a mix of aggressive buybacks (Lloyds Banking Group completing a £1.75B program) and dilutive financing (Black Hawk Acquisition's $200M SEPA). The period-over-period data is limited in this batch, but forward-looking statements and insider activity provide actionable signals for the upcoming trading session.

30 high priority 20 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — September 24, 2026

The sole contract in this digest is a $237.8 million firm-fixed-price award to M. A. Mortenson Company by the National Institutes of Health (NIH) for design-build construction of a clinical and computational science building in Bethesda, MD. This is a civilian, non-defense award, representing a fully funded, multi-year revenue stream with no options or set-asides. The highest-conviction signal is the full upfront funding and competitive award, indicating strong execution confidence from NIH. A key risk is the firm-fixed-price structure, which transfers cost overrun risk to Mortenson, particularly given the specialized research facility requirements.

1 total filings
· daily

New Federal Contractors — September 24, 2026

The digest covers a single, large civilian contract totaling $237.8 million awarded to M. A. Mortenson Company by the National Institutes of Health (NIH) for a clinical and computational science building in Bethesda, MD. This is a fully funded, firm-fixed-price delivery order with no options, providing multi-year revenue visibility through March 2031. The contract is bullish for Mortenson, signaling strong competitive positioning in specialized research facility construction, but carries medium execution risk due to the fixed-price structure. Key watch items include cost overruns and NIH construction budget trends.

1 total filings
· daily

Significant Contract Modifications ($10M+) — September 24, 2026

This digest covers a single, large civilian contract: a $237.8 million firm-fixed-price award to M. A. Mortenson Company from the National Institutes of Health (NIH) for a clinical and computational science building. The contract is fully funded with no options, providing multi-year revenue visibility through March 2031, but carries execution risk typical of fixed-price construction. As a civilian agency award, it is less exposed to DoD budget volatility but still subject to broader federal construction spending trends. The highest-conviction signal is the full upfront funding, which de-risks the revenue stream for Mortenson. Key watch items include potential cost overruns on the fixed-price structure and NIH budget trends for follow-on awards.

1 total filings
· daily

Contract Deobligations Alert — September 24, 2026

This digest covers a single, large civilian contract: a $237.8 million firm-fixed-price award from the National Institutes of Health (NIH) to M. A. Mortenson Company for a clinical and computational science building. The contract is fully funded with no options, providing multi-year revenue visibility for Mortenson through March 2031. The highest-conviction signal is the bullish revenue stream for a non-defense contractor in the specialized research facility construction sector, though the firm-fixed-price structure carries medium execution risk. The key watch item is monitoring Mortenson's quarterly earnings for revenue recognition and any cost overrun disclosures that could impact profitability.

1 total filings
· daily

Contract Option Exercises — September 24, 2026

This digest covers a single, large civilian contract award: a $237.8 million firm-fixed-price delivery order from the National Institutes of Health (NIH) to M. A. Mortenson Company for the design-build of a clinical and computational science building in Bethesda, MD. With zero defense-related contracts in the period, the investment story is entirely civilian, focused on the stable, long-term capital construction needs of the federal health research apparatus. The highest-conviction signal is the full upfront funding and multi-year (4.3-year) revenue visibility for Mortenson, though the firm-fixed-price structure introduces execution risk on a project of this scale. Key watch items include cost overrun disclosures and the trajectory of NIH construction budgets for potential follow-on awards.

1 total filings
· daily

All HHS Contracts — September 24, 2026

The sole contract in this period is a $237.8 million firm-fixed-price award from the National Institutes of Health to M. A. Mortenson Company for the design-build construction of a clinical and computational science building in Bethesda, MD. This is a civilian (HHS) contract with no defense linkage, representing a fully funded, multi-year revenue stream for Mortenson through March 2031. The highest-conviction signal is the full upfront funding and competitive award, which provides strong revenue visibility but carries execution risk due to the fixed-price structure. Key watch items include cost overruns, change orders, and NIH construction budget trends.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 24, 2026

This digest covers a single $237.8 million civilian mega-contract awarded to M. A. Mortenson Company by the National Institutes of Health (NIH) for design-build construction of a clinical and computational science building in Bethesda, MD. The contract is fully funded upfront with no options, providing Mortenson with a low-risk, multi-year revenue stream of approximately $55 million annually through March 2031. As a civilian agency award under full and open competition, it signals stable demand for specialized research facility construction but carries medium execution risk due to its firm-fixed-price structure. The absence of defense contracts in this period highlights a civilian-led procurement environment, with the key watch item being Mortenson's ability to manage cost overruns on this complex project without eroding margins.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 24, 2026

The sole contract in this period is a $237.8 million firm-fixed-price delivery order from the National Institutes of Health (NIH) to M. A. Mortenson Company for the design-build of a clinical and computational science building in Bethesda, MD. This is a civilian (non-defense) award, representing a fully funded, multi-year project with no options, signaling strong budget commitment from NIH. The contract provides Mortenson with significant revenue visibility of approximately $55.3 million annually through March 2031, but the fixed-price structure introduces execution risk. The highest-conviction signal is the bullish revenue visibility for Mortenson, while the key risk is potential cost overruns on a complex construction project. Investors should monitor Mortenson's earnings for revenue recognition and any change orders that could impact margins.

1 total filings
· daily

General Federal Contracts — September 24, 2026

This digest covers a single, large civilian contract awarded by the Department of Health and Human Services (NIH) to M. A. Mortenson Company worth $237.8 million, with no defense-related content. The award is a firm-fixed-price delivery order for a specialized research facility in Bethesda, MD, signaling a fully funded, multi-year revenue stream for Mortenson through March 2031. The highest-conviction signal is the bullish revenue visibility, though the fixed-price structure introduces medium execution risk. Key watch items include cost overrun disclosures and NIH budget trends for potential follow-on work.

1 total filings